Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) – Research analysts at Wedbush lifted their FY2019 earnings estimates for shares of Eiger Biopharmaceuticals in a research report issued on Thursday, November 14th. Wedbush analyst L. Moussatos now anticipates that the biotechnology company will earn ($3.18) per share for the year, up from their previous estimate of ($3.22). Wedbush also issued estimates for Eiger Biopharmaceuticals’ Q4 2019 earnings at ($0.80) EPS, Q1 2020 earnings at ($0.80) EPS, Q2 2020 earnings at ($0.82) EPS, Q3 2020 earnings at ($0.83) EPS, Q4 2020 earnings at ($0.82) EPS, FY2020 earnings at ($3.27) EPS, FY2021 earnings at ($3.21) EPS and FY2022 earnings at ($2.52) EPS.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.76) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.01).
Eiger Biopharmaceuticals stock opened at $11.24 on Monday. The stock has a market capitalization of $283.41 million, a PE ratio of -2.94 and a beta of 1.02. Eiger Biopharmaceuticals has a 12 month low of $8.40 and a 12 month high of $15.33. The business has a 50 day simple moving average of $10.66 and a 200-day simple moving average of $10.76. The company has a debt-to-equity ratio of 0.44, a current ratio of 6.83 and a quick ratio of 6.83.
Several institutional investors have recently bought and sold shares of EIGR. Bank of Montreal Can purchased a new stake in shares of Eiger Biopharmaceuticals during the second quarter worth approximately $28,000. Lindbrook Capital LLC purchased a new stake in shares of Eiger Biopharmaceuticals during the third quarter worth approximately $36,000. Tower Research Capital LLC TRC increased its position in shares of Eiger Biopharmaceuticals by 1,719.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,895 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 4,626 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Eiger Biopharmaceuticals during the second quarter worth approximately $113,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Eiger Biopharmaceuticals during the second quarter worth approximately $179,000. Institutional investors and hedge funds own 84.36% of the company’s stock.
About Eiger Biopharmaceuticals
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.
Featured Article: What does an inverted yield curve signify?
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.